1. Specific in vitro interferon-gamma and IL-2 production as biomarkers during treatment of chronic Q fever
- Author
-
Teske Schoffelen, Marjolijn C.A. Wegdam-Blans, Yvonne E. P. Soethoudt, Jos W. M. van der Meer, Marjolijn J. H. Pronk, Marcel van Deuren, Mihai G. Netea, Chantal P. Bleeker-Rovers, and Anne Ammerdorffer
- Subjects
Microbiology (medical) ,Interleukin 2 ,medicine.drug_class ,Antibiotics ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,lcsh:QR1-502 ,Q fever ,Microbiology ,lcsh:Microbiology ,Interferon-gamma ,Interferon ,medicine ,cell-mediated immunity ,Interferon gamma ,Original Research Article ,biology ,treatment ,business.industry ,Interleukin ,Coxiella burnetii ,biology.organism_classification ,medicine.disease ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Serology ,Immunology ,Biomarker (medicine) ,Interleukin-2 ,biomarker ,business ,Q Fever ,medicine.drug - Abstract
Contains fulltext : 153993.pdf (Publisher’s version ) (Open Access) BACKGROUND: Antibiotic treatment of chronic Q fever is cumbersome and of long duration. To monitor treatment, there is a need for alternative biomarkers. Coxiella burnetii-specific interferon (IFN)-gamma and interleukin (IL)-2 production reflect the type of effector and memory T-cell response. In chronic Q fever, C. burnetii-specific IFN-gamma production is higher and IL-2 production is lower than in individuals with past Q fever. Here we explore whether C. burnetii-specific IFN-gamma and IL-2 production correlate to treatment response. METHODS: We studied the longitudinal C. burnetii-specific IFN-gamma/IL-2 ratio in fifteen proven chronic Q fever patients. All patients were followed for at least 18 months during antibiotic treatment. Treatment was considered successful when clinical recovery was observed, a positive PCR for C. burnetii DNA in blood became persistently negative, anti-phase I IgG showed a fourfold decrease or more, and imaging techniques showed disappearance of infectious foci. RESULTS: Overall, the IFN-gamma/IL-2 ratio declined when patients experienced a successful treatment outcome. When treatment failed, IFN-gamma/IL-2 ratios did not significantly decrease. The median (+/-IQR) slope of the longitudinal IFN-gamma/IL-2 ratio with successful treatment was -2.10 (-7.02 to -0.06), and -0.15 (-1.13 to 0.25) with unsuccessful treatment (P = 0.19). Q fever endocarditis patients had higher IFN-gamma/IL-2 ratios than patients with endovascular infections. CONCLUSION: We propose that the IFN-gamma/IL-2 ratio can be used as an additional biomarker for monitoring chronic Q fever treatment, with declining ratios being indicative of successful treatment.
- Published
- 2015